TXNIP and familial dilated cardiomyopathy: Therefore, understanding the molecular mechanism of the NLRP3 inflammasome activation and targeting specifically the NLRP3 inflammasome and its interacting counterparts (e.g., TXNIP) will be of great value in clinical management of DCM and other CVD (Singh, 2014; Butts et al., 2015).